What is Celltex Therapeutics?
Celltex Therapeutics is a prominent entity in the field of adult stem cell banking and therapy, operating under FDA cGMP compliance. The company specializes in the cultivation of unmodified mesenchymal stem cells, offering services designed for natural health management, longevity, and the treatment of various conditions including chronic pain, injury recovery, and general wellness. Their proprietary cultivation process ensures high purity and potency for banked stem cells, available to individuals of all ages. Celltex actively engages in client education through webinars and personalized consultations to assess the suitability of their stem cell therapies.
How much funding has Celltex Therapeutics raised?
Celltex Therapeutics has raised a total of $35M across 3 funding rounds:
Private Equity
$34.1M
Debt
$350K
Debt
$605K
Private Equity (2012): $34.1M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Debt (2021): $605K supported by PPP
Key Investors in Celltex Therapeutics
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Celltex Therapeutics?
With the recent influx of capital, Celltex Therapeutics is poised for significant expansion. The strategic investment suggests a focus on enhancing its proprietary stem cell cultivation technology, potentially broadening its therapeutic applications, and increasing market penetration. Future developments may include further research into chronic disease management and regenerative therapies, solidifying its position as a leader in the personalized stem cell market. The company's commitment to education and client-specific treatment plans will likely remain a cornerstone of its growth strategy.
See full Celltex Therapeutics company page
